Morgan Stanley Arbutus Biopharma Corp Transaction History

Morgan Stanley

$1.39 Trillion
Q4 2024

A detailed history of Morgan Stanley transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Morgan Stanley holds 22,586,918 shares of ABUS stock, worth $77.7 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

22,586,918

Previous 21,708,451 4.05%

Holding current value

$77.7 Million

Previous $83.6 Million 11.63%

% of portfolio

0.01%

Previous 0.01%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$3.18 - $4.2 $2.79 Million - $3.69 Million	878,467 Added 4.05%	22,586,918 $73.9 Million
Q3 2024 Nov 14, 2024	BUY	$3.12 - $4.56 $2.33 Million - $3.41 Million	748,183 Added 3.57%	21,708,451 $83.6 Million
Q2 2024 Oct 17, 2024	BUY	$2.52 - $3.63 $30.6 Million - $44 Million	12,129,971 Added 137.37%	20,960,268 $64.8 Million
Q2 2024 Aug 14, 2024	BUY	$2.52 - $3.63 $30.6 Million - $44 Million	12,129,971 Added 137.37%	20,960,268 $64.8 Million
Q1 2024 Oct 17, 2024	SELL	$2.26 - $2.92 $27.4 Million - $35.4 Million	-12,129,971 Reduced 57.87%	8,830,297 $22.8 Million
Q1 2024 Aug 16, 2024	BUY	$2.26 - $2.92 $4.17 Million - $5.39 Million	1,846,185 Added 26.43%	8,830,297 $22.8 Million
Q1 2024 May 15, 2024	BUY	$2.26 - $2.92 $4.17 Million - $5.39 Million	1,846,185 Added 26.43%	8,830,297 $22.8 Million
Q4 2023 Aug 16, 2024	SELL	$1.69 - $2.54 $23.6 Million - $35.5 Million	-13,976,156 Reduced 66.68%	6,984,112 $17.5 Million
Q4 2023 Feb 13, 2024	BUY	$1.69 - $2.54 $2.91 Million - $4.38 Million	1,722,982 Added 32.75%	6,984,112 $17.5 Million
Q3 2023 Nov 15, 2023	BUY	$1.9 - $2.27 $343,584 - $410,493	180,834 Added 3.56%	5,261,130 $10.7 Million
Q2 2023 Aug 14, 2023	BUY	$2.24 - $3.06 $442,823 - $604,928	197,689 Added 4.05%	5,080,296 $11.7 Million
Q1 2023 May 15, 2023	BUY	$2.23 - $3.1 $10.3 Million - $14.4 Million	4,640,713 Added 1918.49%	4,882,607 $14.8 Million
Q4 2022 Feb 14, 2023	BUY	$1.91 - $2.85 $57,086 - $85,180	29,888 Added 14.1%	241,894 $563,000
Q3 2022 Nov 14, 2022	SELL	$1.88 - $2.88 $13,062 - $20,010	-6,948 Reduced 3.17%	212,006 $405,000
Q2 2022 Oct 27, 2022	BUY	$1.98 - $3.17 $43,110 - $69,020	21,773 Added 11.04%	218,954 $595,000
Q2 2022 Aug 15, 2022	BUY	$1.98 - $3.17 $43,110 - $69,020	21,773 Added 11.04%	218,954 $595,000
Q1 2022 Oct 27, 2022	SELL	$2.42 - $3.98 $52,690 - $86,656	-21,773 Reduced 9.94%	197,181 $587,000
Q1 2022 May 13, 2022	SELL	$2.42 - $3.98 $101,218 - $166,467	-41,826 Reduced 17.5%	197,181 $587,000
Q4 2021 Feb 14, 2022	BUY	$3.11 - $4.61 $55,429 - $82,164	17,823 Added 8.06%	239,007 $930,000
Q3 2021 Nov 15, 2021	BUY	$2.65 - $4.62 $586,137 - $1.02 Million	221,184 New	221,184 $950,000

Others Institutions Holding ABUS

# of Institutions

165

Shares Held

102M

Call Options Held

649K

Put Options Held

666K

View Full List

About Arbutus Biopharma Corp

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $516M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

More about ABUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account